MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2024.12.010

Медицинская библиотека · Transplantation and cellular therapy · 2024

Letermovir for Prevention of Recurrent Cytomegalovirus in High-Risk Allogeneic Hematopoietic Cell Transplantation Recipients.

Han Gyuri, Stern Anat, Lee Yeon Joo, Li Yuxuan, Dahi Parastoo B, Tamari Roni, Gyurkocza Boglarka, Jakubowski Ann A, Papadopoulos Esperanza B, Shaffer Brian, Perales Miguel-Angel, Obeid Karam M, Young Jo-Anne H, Papanicolaou Genovefa A

СтатьяПеревод в очереди

Аннотация

We evaluated letermovir (LTV) for secondary prophylaxis for cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant recipients (HCT) at high-risk for CMV recurrence. This open-label study was conducted at Memorial Sloan Kettering Cancer Center and the University of Minnesota. Patients with clinically significant CMV infection (cs-CMVi) and ≥1 high-risk criteria for CMV who achieved viral suppression with standard CMV antivirals received LTV secondary prophylaxis for up to 14 weeks. The primary endpoint was cs-CMVi at week 14; secondary endpoints included LTV resistance, CMV end-organ disease (EOD), CMV-related death, and LTV-related adverse events at week 14. Thirty-six patients were analyzed (CMV seropositive, n = 33; T cell-depleted HCT, n = 25; cord blood allograft, n = 5). By week 14 post-transplantation, 5 patients met the primary endpoint of cs-CMVi, for a cumulative incidence of 14.9% (95% confidence interval, 2.6% to 27.1%). Four patients developed LTV breakthrough cs-CMVi (including 2 patients with confirmed LTV resistance). The remaining patient developed rebound cs-CMVi after premature discontinuation of LTV due to enrollment in a clinical trial. There were no cases of CMV EOD, CMV-related death, or LTV-related adverse events by week 14 or by week 24. Our data support that LTV secondary prophylaxis is safe and effective in high-risk HCT recipients.

Для цитирования: Han Gyuri, Stern Anat, Lee Yeon Joo, Li Yuxuan, Dahi Parastoo B, Tamari Roni, Gyurkocza Boglarka, Jakubowski Ann A, Papadopoulos Esperanza B, Shaffer Brian, Perales Miguel-Angel, Obeid Karam M, Young Jo-Anne H, Papanicolaou Genovefa A. Letermovir for Prevention of Recurrent Cytomegalovirus in High-Risk Allogeneic Hematopoietic Cell Transplantation Recipients.. Transplantation and cellular therapy. 2024. DOI: 10.1016/j.jtct.2024.12.010.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.